Early on his tenure, Wolgen made reference to this drug having blockbuster potential.
Now, in the TR India interview, he says:
"In first instance, Afamelanotide will probably not qualify for the label blockbuster potential.
Well isn't that interesting...
Like I said, we would not be sitting at .26 at this stage if we were going to see massive sales anytime soon from this. The new model of the business precludes this IMO.
They had better find an additional pillar to build the business on if they plan a billion dollar business. I don't see how, from a financial standpoint, you can do that without huge sales from a one-trick pony. Multiple indications, yes, but still just one drug compound in their current arsenal.
And it seems to me it's pretty hard to diversify into other compounds. They don't have the cash to make an acquisition and they are not as far as we know working on completely separate compounds for study.
Early on his tenure, Wolgen made reference to this drug having...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |